EGFR tyrosine kinase inhibitors alone or in combination with chemotherapy for non-small-cell lung cancer with EGFR mutations: A meta-analysis of randomized controlled trials
Conclusion: Our meta-analysis shows that EGFR TKIs with chemotherapy confer better OS and ORR compared to either treatment alone, similarly, the combined treatment showed better PFS and ORR profiles than the use of TKI alone.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Cui-Min Zhu Xiang-Yao Lian Hong-Yan Zhang Lu Bai Wen-Jing Yun Ru-Han Zhao Qing-Shan Li Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Databases & Libraries | Lung Cancer | Non-Small Cell Lung Cancer | Study